Skip to main content
Premium Trial:

Request an Annual Quote

Rebecca Galler Robison, Stephan Herrera, Robert Schaub, Page Bouchard

Rebecca Galler Robison, senior director of corporate strategy for Sirna Therapeutics, has left the RNAi drug developer. Assuming her duties is Stephan Herrera, who has become Sirna’s executive director of investor relations.
According to Herrera, Robison’s departure was linked to Sirna’s ongoing relocation of employees from its former headquarters on Boulder, Colo., to its new headquarters in San Francisco.

Aptamer drug development firm Archemix said this week that it has appointed Robert Schaub as vice president of preclinical discovery.
Schaub, who was most recently assistant vice president for cardiovascular and metabolic diseases at Wyeth, holds a bachelor's degree in biology from the University of Nevada and a PhD from Washington State University, the company said.

Archemix also announced that Page Bouchard, senior vice president at the company, will head the research and preclinical development group. Bouchard joined Archemix in 2004 as senior vice president of preclinical drug discovery and preclinical development.

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.